title: Prolongation of second heart transplants in rats.
abstract: Second clinical kidney grafts often survive longer than first grafts. Using a rat cardiac allograft model, we examined the conditions under which survival of a second graft can be longer than first graft survival. In the BUF-to-LEW combination, following rejection of the first transplant, second cardiac allografts from the same donor strain implanted immediately survived longer than the first grafts (P = 0.047). Although the mean survival time of first grafts was 9.0 days, second grafts implanted in the same animals survived 19.5 days. In contrast, when ACI donors were used for the same LEW recipients, the second grafts were rejected in 3 days compared with 6.6 days for first grafts. Donor-specific spleen cell transfusions in these combinations resulted in prolonged survival in the BUF to LEW combination, but had no effect when the donor strain was ACI. Second grafts from BUF had prolonged survival following rejection of the first graft. Thus the histocompatibility difference was a determining factor of whether or not prolongation would be obtained. Another factor was timing of the second transplant. If 7 days were allowed to elapse following rejection of the first graft before implantation of the second, the enhancement effect was lost. Moreover, in the LEW-to-ACI combination in which second grafts were rejected rapidly, removal of the first graft after 7 days (before rejection), resulted in prolonged survival of the second graft. There is, therefore, a window of time before rejection of first grafts and shortly thereafter, when the enhancement effect can be obtained. Passive transfer of serum in the BUF-to-LEW combination resulted in enhancement, but transfer of splenic cells was ineffective. We conclude that graft rejection can result in induction of enhancement during a specific period, after which this effect is lost; and that enhancement can be obtained only in certain strain combinations. This suggests that human patients with heart transplants that reject might benefit from a second graft, even from a donor with a mismatch similar to the first graft.
authors.affiliation: UCLA Department of Surgery, UCLA School of Medicine 90024.
authors.forename: A
authors.initials: A
authors.lastname: Yanagiya
authors.forename: P I
authors.initials: PI
authors.lastname: Terasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Iwaki
authors.forename: B B
authors.initials: BB
authors.lastname: Ho
authors.forename: D C
authors.initials: DC
authors.lastname: Drinkwater
authors.forename: H
authors.initials: H
authors.lastname: Laks
mesh_terms: D000818:Animals; D005434:Flow Cytometry; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology*; D007116:Immunization, Passive; D008297:Male; D051381:Rats; D011912:Rats, Inbred ACI; D011915:Rats, Inbred BUF; D011917:Rats, Inbred Lew; D012092:Replantation; D013154:Spleen / Q000166:cytology; D013997:Time Factors